1997
DOI: 10.2337/diacare.20.10.1539
|View full text |Cite
|
Sign up to set email alerts
|

Modification of Postprandial Hyperglycemia With Insulin Lispro Improves Glucose Control in Patients With Type 2 Diabetes

Abstract: Previously, it has not been possible to address the effect of treatment of postprandial hyperglycemia specifically. We have now shown that the treatment of postprandial hyperglycemia with insulin lispro markedly improves overall glucose control and some lipid parameters in patients with type 2 diabetes.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
26
0
5

Year Published

1999
1999
2006
2006

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 75 publications
(32 citation statements)
references
References 0 publications
1
26
0
5
Order By: Relevance
“…Nevertheless, in that study [40] the use of lispro was associated with a lower rate of both total and nocturnal hypoglycaemia episodes (p < 0.01 vs regular human insulin). When insulin lispro was added to antecedent treatment with sulphonylurea in Type II diabetic patients, there was a statistically significant decrease in fasting and postprandial glucose concentrations, HbA 1 c values and serum triglyceride concentrations and a rise in HDL-cholesterol concentrations [94]. No comparison with regular human insulin was, however, made in that study.…”
Section: Reviewmentioning
confidence: 51%
“…Nevertheless, in that study [40] the use of lispro was associated with a lower rate of both total and nocturnal hypoglycaemia episodes (p < 0.01 vs regular human insulin). When insulin lispro was added to antecedent treatment with sulphonylurea in Type II diabetic patients, there was a statistically significant decrease in fasting and postprandial glucose concentrations, HbA 1 c values and serum triglyceride concentrations and a rise in HDL-cholesterol concentrations [94]. No comparison with regular human insulin was, however, made in that study.…”
Section: Reviewmentioning
confidence: 51%
“…Vários estudos prévios demonstraram que o uso de insulina lispro leva a uma redução significante da glicemia pós-prandial quando comparado a insulina regular (17)(18)(19)(20)(21)(22)(23)(24)(25), e alguns estudos também mostraram uma redução significante da HbA 1C em uso de insulina lispro (30)(31)(32)(33). Estes estudos sugerem que, quando os pacientes são transferidos para insulina lispro, a estratégia de tratamento deve ser de ajustar tanto os esquemas de insulinização pré-prandiais quanto o esquema de doses e freqüência da insulina basal (31)(32)(33)(34).…”
Section: Discussionunclassified
“…Como resultado, ela tem um início de ação rápido (15 minutos), atinge um pico de ação mais precocemente (1 hora) e possui uma duração de ação mais curta (4 horas) (6)(7)(8)(9)(10)(11)(12). Estudos clínicos demonstraram que esta insulina monomérica tem efeitos benéficos, como a redução da incidência de episódios hipoglicêmicos (12-16) e um melhor controle glicêmico pós-prandial (17)(18)(19)(20)(21)(22)(23)(24)(25). Além disso, a insulina lispro deve ser administrada imediatamente ou, se necessário, após a refeição, mantendo ação eficaz (26)(27)(28)(29).…”
Section: Introductionunclassified
“…• (14) showed that using insulin lispro to target postprandial hyperglycemia in patients with type 2 diabetes not only improved PPG control but also reduced both fasting glucose and A1C levels from 9.0 to 7.1%. Furthermore, a study by Bastyr et al (15) showed that therapies that focused on lowering PPG versus fasting glucose are better for lowering glycated hemoglobin levels.…”
Section: What Is a Normal Ppg Value?mentioning
confidence: 99%